Description
The use of AI (machine learning) tools in the innovation process, (as well as associated data processing activities) present one of the greatest ethical, legal, social and Policy challenges of the present wave of innovation in the biomedical and pharmaceutical sector. The biotechnology directive has been enacted to: clarify and harmonise patent protection for biotechnology innovation (recitals 1 to 5), which today we can understand as including life science and biomedical innovation. However, it was never intended to create a sector specific patent law rules.This presentation and forthcoming paper discusses how the Biotechnology Directive has codified a body of rules that consist of specifications (lex specialis) to general patent law and applicable to life science innovation. It discusses the future of this legal instrument by reference to the challenges of Artificial intelligence implementation in biomedical innovation. In particular concerning how its rules on subject matter patentability and exceptions to the grant of patents have assumed a technology regulatory role, both directly and indirectly.
| Period | 2023 Sept 14 |
|---|---|
| Event title | 25th Anniversary of the Biotechnology Directive 98/44/EC: A Reflection on its Past, Present and Future |
| Event type | Conference |
| Location | Dublin, IrelandShow on map |
| Degree of Recognition | International |
Documents & Links
- Program - Conference on the 25th Anniversary of the Biotechnology Directive
File: application/pdf, 1.57 MB
Type: Text
Related content
-
Projects